Explore the Agenda
7:30 am Check-In & Light Breakfast
8:20 am Programme Director’s Opening Remarks
8:25 am Chair’s Opening Remarks
Looking Beyond GLP-1 to Detect New Potential Therapies for Enhanced Metabolic Control & Weight Management
9:00 am Tissue-Specific Mitochondrial Uncoupling: A Novel Strategy to Enhance Energy Expenditure in Obesity Treatment
- Focusing on energy expenditure mechanisms to complement current appetite-modulating therapeutic approaches
- Discovery and characterization of an adipose tissue-enriched small molecule mitochondrial uncoupler that enhances energy expenditure
- Demonstrating preclinical efficacy and safety by adipose-enriched mitochondrial uncoupling
9:30 am Beyond Rapid Weight Loss: Harnessing Gut-Brain Signalling for Sustainable Metabolic Health
- Targeting sugar stimulation to reactivate nutrient-sensing cells to restore natural hormonal signalling and neural communication in the brain
- Focusing on rejuvenation to avoid aggressive weight loss and rebound effects for improved long-term adherence
- Promoting microvascular and multi-organ benefits by restoring systemic balance for better alignment with payer demands for cardio-metabolic endpoints
10:00 am Speed Networking
Put a face to a name: this session is the perfect opportunity to get face-to-face time with key opinion leaders, leading companies, and innovative researchers in the obesity drug development field. Establish meaningful connections to build upon for the rest of the conference and gain individual insight beyond the papers and press releases into pioneering research and technique applications.
10:45 am Morning Break
11:00 am Panel Discussion: Expanding the Obesity Drug Development Pipeline from Peripheral Targets to Holistic Metabolic Health
- Exploring beyond traditional targets to understand how peripheral pathways and novel mechanisms address unmet needs in obesity care
- Integrating multi organ approached from gut-brain signalling with systemic metabolic health for synergistic efficacy to address payer demands, and drive adherence and market access
- Translating preclinical insights into clinically viable non-incretin therapies to diversify obesity drugs and move from placebo to active comparator trials
11:30 am Roundtable Discussion: Overcoming Commercial & Clinical Challenges to Advance the Next-Generation of Obesity Therapeutics
- Balancing rapid weight loss with microvascular and metabolic health preservation to mitigate rebound effects and enhance reimbursement potential
- Understand regulatory and patient advocacy perspectives to improve trial retention
- Exploring ethical trial design for the next gen-generation of obesity therapies to provide robust evidence for regulatory and commercial success
12:00 pm Investigating Emerging Targets to Neuronal Pathways & Energy Expenditure for the Development of Novel Obesity Treatments
- Examining neuronal expenditure pathways to complement appetite suppression for increased therapeutic alternatives
- Understanding emerging targets of mitochondrial activators for improved treatment of low-metabolic rate phenotypes
- Targeting novel receptor pathways to enhance therapeutic efficacy in obesity with comorbid diabetes, addressing a key unmet clinical need
12:30 pm Lunch
Spotlighting the Next Wave of Obesity Therapeutics to Highlight the Innovation in Targets & Modalities for Transformative Efficacy
1:30 pm New Insights into Regulation of Energy Metabolism by GIPR Agonism & Antagonism
- Exploring the preclinical delineation of the effects GIP agonism vs. antagonism on food intake and metabolism
- Discovering mechanisms of GLP-1/GIP dual agonism in the brain to accelerate the design of triple-agonists with improved tolerability
- Proposing patient stratification strategies for GIP-targeted therapies to address heterogeneity in response, mitigating trial risks and expanding treatable populations
2:00 pm MyoScreen™: Leading the Discovery of Innovative Skeletal Muscle-Targeting Drugs for Healthy Weight Loss
- Highlighting novel platforms to identify muscle-preserving therapies for obesity
- Addressing sarcopenia risks during weight loss with targeted drug discovery
- Demonstrating preclinical-to-clinical translation of muscle-centric metabolic interventions
2:10 pm Revealing DNA-Encoded Incretin Mimetics for Sustained Therapeutic Effects
- Investigating a novel DNA-based platform for sustained in vivo GLP-1 production following a single administration
- Examining DNA electroporation for delivery of brain-targeted incretin mimetics for precise hunger modulation
- Assessing strategies for half-life extension of incretin to reduce dosing frequencies for improved patient adherence
2:40 pm Breaking New Ground in Obesity Therapeutics From Novel Mechanisms to Patient-Centric Solutions
- Expanding the therapeutic arsenal to target neuronal and metabolic pathways for more effective obesity treatments
- Demonstrating superior fat-loss preservation and GI tolerability in next-gen incretin therapies with brain-specific mechanisms to enable personalised obesity treatment
- Innovating delivery systems from DNA-encoded therapies to oral formulations for sustained peptide delivery
3:10 pm Roundtable Discussion: Bridging Innovation & Commercialisation to Overcome Barriers in Novel Obesity Modalities
- Transitioning from preclinical neuronal and mitochondrial targets to clinical development to diversify mechanisms and reduce reliance on incretins
- Optimise delivery methods to enhance precision and durability of therapies and lower long-term costs
- Designing adaptive trials for GIPR- and DNA-based therapies to mitigate risks in heterogenous patient populations and accelerate regulatory approval
3:30 pm Afternoon Break & Poster Session
Connect with peers in a relaxed atmosphere and continue to forge new and existing relationships while exploring the latest in obesity drug development approaches and research advancements. To submit a poster, please contact info@hansonwade.com
Spotlighting the Next Wave of Obesity Therapeutics to Highlight the Innovation in Targets & Modalities for Transformative Efficacy – Continued
4:00 pm Evaluating Lipidated IL-22 Analogues for Obesity to Restore Metabolic Homeostasis Through a Gut-Acting Mode-of-Action for Clinically Meaningful Outcomes
- Explore how CK-0045, a first-in-class IL-22 agonist being investigated in a Phase 2a study, offers a unique approach to obesity treatment through a novel non-incretin-based mode-of-action in the gut which preserves muscle mass during weight loss
- Understand the potential of CK-0045 to be used as a standalone therapy or in combination with current standard treatments, offering a broader spectrum of benefits that address both weight loss and deeper metabolic improvements
4:30 pm RNA-Based Therapy to Increase Energy Expenditure & Promote Quality Body Weight Loss, Preserving Lean Mass
- RES-101, a first-in-class miR-22 inhibitor, restores lipid biosynthesis and drives adipose browning for sustained reduction of unhealthy fat and improved body composition
- Disease-modifying approach that can be synergistically combined with other therapeutic modalities
- Selectively addressing excess of adiposity to promote high quality body weight loss
5:30 pm Panel Discussion: Exploring Pathways in Obesity Treatment From Inflammation to RNA & Hypothalamic Precision
- Targeting inflammation to restore metabolic homeostasis and leverage dual action therapies for metabolic restoration and reduction in chronic inflammation
- Promoting adipose browning and lean mass retention through RNA-Based miR-22 inhibition for fat remodelling and improved body composition